Bio, Inc. has received an exclusive license from the University of
Alabama at Birmingham (UAB) for the underlying patent to commercialize a
novel diagnostic tool and early-stage treatment for Crohn’s disease, a
type of inflammatory bowel disease. The Company’s co-founder and Chief
Scientific Officer, Dr. Charles Elson, and his laboratory at UAB were
responsible for the research efforts that led to the groundbreaking
discoveries.
“We look forward to advancing this promising therapy for the patients who need it.”
ImmPrev Bio has identified that more than half of Crohn’s disease
sufferers have immune responses to a particular subset of gut bacteria.
Moreover, patients with a high immune response to this antigen are
likely to experience more Crohn’s disease complications. Based on this
science, the Company is developing a concomitant metabolic checkpoint
inhibition therapy for Crohn’s disease. With strong preclinical
proof-of-concept data supporting this approach, ImmPrev Bio will first
target patients in surgically or medically induced remission from
Crohn’s disease as well as patients with new-onset Crohn’s who
demonstrate a high anti-flagellin response. ImmPrev Bio believes this
approach can lead to a platform for treating other immune-mediated
diseases in addition to Crohn’s.
“We believe that our novel early-stage treatment model has the potential
to enable better outcomes for Crohn’s patients, who can now be
identified earlier and tracked and treated more effectively,” said Dr.
Elson, Chief Scientific Officer of ImmPrev Bio. “We look forward to
advancing this promising therapy for the patients who need it.”
First Avenue Ventures Life Science Fund I, a fund with a strategic focus
on Birmingham-based early-stage investment opportunities in the life
sciences, recently led an investment round into ImmPrev Bio.
Additionally, the Fund plans to support business development and
commercialization efforts. “We are thrilled to be working with Dr. Elson
on this innovative diagnostic and therapy for Crohn’s disease,” said
Mike Goodrich, Principal of the First Avenue Ventures Life Science Fund
I. “We are also proud to have invested in ImmPrev Bio, a company
building on Elson’s outstanding research to develop a treatment with the
potential to offer new hope for Crohn’s disease patients.”
ImmPrev Bio has engaged Cascadia Drug Development Group to help support
the commercialization efforts. The group was founded by seasoned
industry experts who are passionate about immunology and drug
development. The team is working with other strategic partners to
conduct additional pre-clinical experiments to confirm the lead compound
and advance towards IND-enabling studies.
About ImmPrev Bio, Inc.
ImmPrev Bio is a company dedicated to the development and
commercialization of a novel method of treatment for patients suffering
from Crohn’s disease, a type of inflammatory bowel disease. This
approach is based on the research efforts of Dr. Charles Elson, Basil I.
Hirschowitz Chair in Gastroenterology and Professor of Medicine,
Microbiology, and Surgery at the University of Alabama at Birmingham.
--
Starred by:
im4aubie
aubie in bham
Aubiece
WDE mobile
Son of Null
IBleedMaroonDawg
AU Forever
Hobbes
FLVOL
PharmaTiger
iPhoneHobbes
Mudlizard
Chemosabe
BATJAC1
Rebel1
yt
Inspector Vol
Top Cat
J.M.
--
